[1] |
WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken .
Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
|
[2] |
CAI Zuhuan, DENG Taomei, WEI Naijie, ZHU Dan, QIAN Fei, WANG Guangji, ZHANG Jingwei.
Silybin ameliorates lipid metabolism disorders in mice with non-alco-holic steatohepatitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 241-248.
|
[3] |
MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling.
Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
|
[4] |
ZHANG Liang, LIAO Yongqun, XIA Qinchuan, ZHOU Shitong, LI Xiaoli.
Ferroptosis regulatory signaling pathway and its research progress in related diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 227-234.
|
[5] |
SONG Ruzheng, PENG Ying, WANG Guangji, SUN Jianguo.
Commonly used quantitative proteomics research techniques and their application in the study of pathogenesis of liver-derived diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 570-578.
|
[6] |
JIANG Weijie, HE Haibo, TANG Hongbo, HE Junyu.
Research progress on the relationship between nuclear factor-κB in placenta and pregnancy complications
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 82-87.
|
[7] |
WU Jiayuan, ZHENG Li, MO Juanfen, GUO Li, CAO Chenxi, BAO Yi.
Regulation of N-acetylcysteine on peripheral circulatory and hepatic myeloid-derived suppressor cells in non-alcoholic fatty liver disease mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 989-996.
|
[8] |
CHEN Xi, LING Jiawei, DING Jiaxin, JIANG Zhenzhou, ZHANG Luyong.
Advances in pathogenesis of nonalcoholic fatty liver disease caused by tamoxifen
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 715-720.
|
[9] |
ZHOU Hongping, YANG Xingxin, ZHUANG Rangxiao, SHAO Yidan, XI Jianjun, LIAO Li, REN Bailu, WANG Pingping, YU Shuying, SHI Tingting.
Effects of activated carbon N-acetylcysteine sustained-release microcapsule on miRNA of non-alcoholic fatty liver disease in young rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 263-270.
|
[10] |
YANG Yilin, ZHENG Linying, GU Weiming, PAN Jingqiang, WU Xin,LI Yaojun.
Effect of total glucosides of paeony regulate HMGB1, RAGE pathway on nonalcoholic fatty liver disease in rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 611-616.
|
[11] |
CHEN Dan, LIN Xiuxian, CHEN Yao.
Research on the progress of alcoholic liver disease pathogenesis related to CYP2E1
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 198-203.
|
[12] |
LI Xiaoli, SHA Nannan, CHEN Nan, WANG Yongjun, ZHANG Yan.
Experimental study progress of smoking- and alcohol-induced osteoporosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1299-1303.
|
[13] |
LIN Xiuxian, CHEN Dan, ZHAO Qing, CHEN Yao.
Genetic research on the incidence of alcoholic liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1309-1314.
|
[14] |
LU Yong-juan, CHEN Zhi-yun, YAN Mao-xiang, HE Bei-hui, ZHU Dan.
Effect of atorvastatin on adipokines in rats with nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 520-524.
|
[15] |
JI Xue-lei, GE Yi-dong, AN Min-min, LIU Lei, DING Jun, XIE Yu-xin, LI Chun-yun.
Correlation analysis between nonalcoholic fatty liver disease and metabolic syndrome
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 666-670.
|